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Patients’ experiences of diagnosis and
management of papillary thyroid
microcarcinoma: a qualitative study
Brooke Nickel1,2 , Juan P. Brito3, Ray Moynihan1,4, Alexandra Barratt1, Susan Jordan5,6 and Kirsten McCaffery1,2*
Abstract
Background: In recent years management practices in relation to low-risk papillary microcarcinoma (PMC) have
been evolving with increased awareness of the potential overdiagnosis and overtreatment of PMCs, and guidelines
recommendations for non-surgical management options such as active surveillance. This study aimed to develop
an in-depth understanding of patients’ experiences of the communication of their PMC diagnosis, their treatment
preferences and decision making.
Methods: Semi-structured qualitative interviews with 25 patients diagnosed pre-operatively with PMC < 1 year since
their diagnosis and treatment. Interviews were conducted between September 2015 and July 2016 and were
audio-recorded and transcribed verbatim. Framework analysis method was used to analyse the data.
Results: The diagnosis and treatment experience of PMC patients varied widely. The majority of patients were
asymptomatic, and their PMC was initially detected via an imaging test requested for a reason unrelated to a thyroid
disorder or symptom. Clinicians generally described PMC to patients as being a “small” or “slow-growing” cancer,
and there was little evidence that clinicians had discussions about the possibility of overdiagnosis or
overtreatment. Overall, surgery was the only option discussed and offered to patients. Patients preference for
treatment was largely based on eliminating the possibility of the cancer spreading (thyroidectomy) or not
wanting to be on thyroid replacement medication for the rest of their life (hemi-thyroidectomy). Many patients
reported emotional and physical side-effects associated with their diagnosis and treatment, however patients
generally indicated that active surveillance is not something they would have been interested in if it was offered
to them.
Conclusions: Evidence continues to emerge that many patients with PMCs may be overdiagnosed, and management
guidelines are recommending more conservative management options for these patients. As a result, shared decision
making around treatment options is vital so that patients are fully aware of the meaning of their diagnosis and their
management options including active surveillance. Importantly, interventions to reduce unnecessary diagnoses of PMC
are critically needed.
Keywords: Papillary thyroid cancer, Communication, Decision making, Treatment preferences, Overdiagnosis,
Overtreatment
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Background
Papillary thyroid cancer (PTC) accounts for approximately
90% of all thyroid malignancies. The recent increase in the
incidence of PTC [1] is largely due to the surge in the
diagnosis of small (< 1 cm) PTCs [2], also known as papil-
lary microcarcinomas (PMCs). It is highly probable that
the introduction and growing use of imaging techniques
(e.g. computed tomography (CT), high resolution ultra-
sound) has increased the detection of PMCs from a sub-
stantial reservoir of thyroid cancer [3]. This has raised
concerns about overdiagnosis and in turn the overtreat-
ment of patients diagnosed with PMC [4, 5].
Patients with PMC are usually treated surgically with
either complete (total thyroidectomy) or partial (hemi-
thyroidectomy) removal of the thyroid, although active
surveillance with surgery if disease progression occurs
may be a safe management option. Two observational
studies of active surveillance in patients with PMCs con-
cluded that the rate of loco-regional metastases with ac-
tive surveillance is comparable to the rate that can occur
after thyroid surgery, and that outcomes of surgery
are the same whether the surgery is undertaken im-
mediately or after any progression (tumour growth
≥3 mm or loco-regional metastasis) [6–8]. Moreover,
it has been showed that delayed surgery in patients
initially following active surveillance is safe, and does
not lead to worse outcomes than patients who elected
immediate surgery [9].
In light of recent evidence of the safety of active sur-
veillance to manage patients diagnosed with PMC, the
2015 American Thyroid Association (ATA) guidelines
now suggest that an active surveillance management ap-
proach can be considered as an alternative to immediate
surgery in patients considered to have very low-risk tu-
mours [10]. Clinical practice may now be changing with
some clinicians beginning to offer active surveillance for
low-risk PMC [9, 11].
With increasing awareness of the potential overdiag-
nosis and overtreatment of PMCs, and recent guide-
lines recommendations for active surveillance, it is
important to understand the diagnosis and treatment
experience from the patient perspective. In particular,
understanding the communication around diagnosis
and management options (including active surveillance)
as well as factors that affected decision making may
help patients calibrate prognosis with decision making.
In addition, we were interested to know how a change
in cancer terminology might change patient’s percep-
tions of their diagnosis. To this end, we conducted the
first qualitative study in patients with PMCs to develop
an in-depth understanding of patients’ experiences of
the communication of their PMC diagnosis, their treat-
ment preferences and how their treatment decisions
were made.
Methods
Study design
This qualitative study used semi-structured face-to-face
and telephone interviews to explore PMC patient’s diag-
nostic and treatment experience including communica-
tion and decision making.
Participants
Participants were 25 PMC patients from New South Wales
and Queensland, Australia. Eligible patients were < 1 year
since initial diagnosis and were only included if they had
been diagnosed pre-operatively (before any surgical inter-
vention) with a single focus < 1 cm PTC with no evidence
of extra-thyroidal extension or lymph node metastasis. All
patients were aged 18 years and above and spoke adequate
English as interpreting services were not used in this study.
Recruitment
Patients were purposively recruited through three differ-
ent avenues which included: 1) the Queensland Thyroid
Cancer Study (QTCS) run by the QIMR Berghofer Med-
ical Research Institute in Brisbane, Queensland; 2) pa-
tient clinics at the Chris O’Brien Lifehouse in Sydney,
New South Wales; and 3) an Endocrine surgical database
from the Royal North Shore Hospital in Sydney, New
South Wales.
Eligible patients participating in the QTCS were in-
vited by a research nurse from the QIMR Berghofer
Medical Research Institute to participate in an additional
interview about their thyroid cancer diagnosis. Interested
patients were provided with additional information
about the study and those who gave verbal consent to be
contacted by the University of Sydney researchers were
mailed a letter, Participant Information Sheet (PIS), and
a formal consent form with a reply-paid envelop. Those
who returned the consent form to researchers were
called to arrange a mutually convenient time to conduct
a telephone interview. All patients recruited via the
QTCS were interviewed by telephone as patients lived
throughout the state of Queensland in Australia.
Eligible patients presenting to patient clinics at the
Chris O’Brien Lifehouse were recruited by two thyroid
surgeons. Patients were given an Expression of Interest
(EOI) form along with the study’s PIS. Interested pa-
tients then mailed the EOI form back to researchers in a
reply-paid envelope and once researchers received pa-
tients’ EOI forms, they were contacted via telephone to
set up either a face-to-face or telephone (if appropriate)
interview. Consent forms were signed by the patients in
person before the interview commenced or were mailed
to patients if they were interviewed by telephone.
Recruitment from the Royal North Shore Hospital was
conducted by a research database manager identifying
patients from an Endocrine database of patients who
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had previously consented to be contacted for research
purposes. Patients were identified if they met the eligibil-
ity criteria and were sent a letter, PIS and EOI form.
Once researchers received the EOI form from interested
patients, they contacted patients via telephone to set up
either a face-to-face or telephone (if appropriate) inter-
view. Consent forms were signed by the patients in per-
son before the interview commenced or were mailed to
patients if they were interviewed by telephone.
The research team
Following the COREQ checklist for reporting qualitative
research [12] the research team has expertise in public
health, healthcare communication, endocrinology, gen-
eral medicine, clinical epidemiology, psychology and
overdiagnosis. BN is a PhD candidate and public health
researcher specialising in communication and overdiag-
nosis. JPB is an international endocrinologist who spe-
cialises in thyroid disorders communication and decision
making research. RM is a post-doctoral researcher with
a special interest in overdiagnosis. AB is an epidemiolo-
gist and public health researcher with expertise in cancer
screening and early detection. SJ is a cancer epidemiolo-
gist with special interests in the aetiology and diagnostic
pathways for thyroid cancer. KM is a health psychologist
and senior qualitative researcher with an interest in
overdiagnosis and communication science.
Data collection
The semi-structured interview schedule (seeAdditional file 1)
was developed and revised with advice from an international
endocrinologist who specialises in thyroid cancer communi-
cation and decision making research (JPB), as well as quali-
tative research (KM) and public health (AB) experts. The
interviews were conducted between October 2015 and July
2016, and took place at patients’ homes or by telephone.
The interviewer was a public health researcher with experi-
ence conducting qualitative interviews and using qualitative
research methods (BN). Interviews lasted between 15 and
40 min and were audio-recorded and transcribed verbatim.
Analysis
A thematic analysis of the transcribed interviews was con-
ducted using Framework Analysis to organise the data to
capture the views expressed by patients [13]. To ensure
rigor in the analysis a step-by-step approach was taken by
the research team [14]. The first step was familiarisation of
the data, where one researcher independently reviewed and
made notes on all 25 interview transcripts. Next was the
creation of a thematic framework where 3 researchers (BN,
JB, KM) read a sub-set of transcripts covering a range of
ages and genders, and developed and revised with continu-
ous discussions the framework based on emerging topics
and themes arising from the transcripts. Following the
development of the framework, an additional researcher
(RM) read a further sub-set of interviews and approved the
framework for coding. Coding was done by two researchers
(BN and RM), where BN independently coded all 25 inter-
views into the framework with RM independently double-
coding a random set of 3 interviews. Similarities or differ-
ences in the coding between the two researchers was dis-
cussed and re-assessed. Once coding was complete, BN
and RM examined the framework within and across themes
and participants to identify the overarching themes and re-
lationships. These themes were summarised and checked
by two additional members of the research team (JB and
KM) by each reading an additional transcript. The final re-
sults were further discussed with the entire research team.
Results
Participants were 17 women and 8 men, between 23 and
78 years of age, from a range of demographic back-
grounds and levels of education (see Table 1).
Table 1 Participant characteristics
Characteristic No. of patients
(n = 25)
Age (years)
≤25
26–50
51–75
75+
1
5
18
1
Gender
Female
Male
17
8
Highest level of education
Year 11 or below
High school
Technical or college diploma
Bachelors degree or above
2
2
8
13
Recruitment Avenue
Queensland Thyroid Cancer Study (QTCS)
Chris O’Brien Lifehouse patient rooms
Royal North Shore Hospital endocrine surgical
database
18
2
5
Size of nodule (mm)a
0.0–1.9
2.0–3.9
4.0–5.9
6.0–7.9
8.0-≤ 10.0
3
3
6
6
5
Mode of detectionb
Physical exam finding
Imaging finding
Diagnostic work-up for thyroid abnormality
Case finding
Symptomatic nodule
3
14
3
1
4
aPatient reported, two patients were unsure of the exact size of their nodules.
All nodules were ≤10 mm
bHow the patient came to be diagnosed with PMC from information discussed
during the interview based on Singh Ospina’s definition of mechanism
detection [15]
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From the thematic analysis, study findings were orga-
nised into six main areas to illustrate the themes arising
from patient reports of their experiences and their views
expressed during the interviews: the diagnostic pathway;
understanding of information related to a PMC diagno-
sis; treatment decision making; impact of being diag-
nosed and receiving treatment; terminology and the
effect of the word cancer; and feeling towards active
surveillance.
The diagnostic pathway
Patients reported experiencing different pathways that
ultimately led to their diagnosis. Based on Singh Ospi-
na’s mechanisms of detection definitions [15], most pa-
tients were asymptomatic and their PMC diagnosis was
initiated by an incidental finding during imaging tests
(e.g. CT scan for a pinched nerve). Commonly, general
practitioners (GPs) were the first point of contact and
sent patients for imaging tests or referring patients to
thyroid specialists.
Other patients, whose PMC was not detected during
imaging tests, had their nodules initially identified by ei-
ther a physical examination (palpation of the neck in an
asymptomatic patient); diagnostic work up for symptoms
suggestive of thyroid hormone disorder; case finding
(thyroid cancer screening in an asymptomatic patient
who may have had exposure to nuclear fallout from
Chernobyl); and work up for a symptomatic nodule
(symptoms present e.g. feeling or seeing a lump). These
mechanisms of detection were less common than detec-
tion during an imaging test. See Table 2 for classification
of modes of detection and patient examples.
Patients discussed being unaware of the possibility that
these imaging tests could pick up other conditions. In
particular, no patient discussed or seemed to be aware of
the possibility that thyroid cancer could be identified.
“I was just shocked. Because I… because… I went in to
the… I went in for a scan on the… for the lump on the
back on my neck, and they… and you know, I came
out… you know, with the diagnosis of cancer.” (female,
age 51–75, imaging finding)
Once a thyroid nodule was identified patients were di-
rected to have an ultrasound guided fine needle aspir-
ation biopsy (USFNA) to determine whether the nodule
was malignant. In general patients were advised to have
an USFNA without any discussion of whether there
might be alternative options or what the consequences
of having it might be. Overall, requesting a biopsy
seemed to be an almost automatic recommendation
from the clinician following identification of a nodule. A
few patients did not even seem sure why a biopsy was
needed in the first place.
“Before I went to go get the biopsy I think I wasn’t
really quite sure why. But then I kind of thought
maybe it was because they didn’t want to scare me
with the information if it wasn’t actually needed.”
(female, age ≤ 25, symptomatic nodule)
Understanding of information related to a PMC diagnosis
Information regarding a diagnosis of PMC was commu-
nicated to patients by various clinicians. Overall, most
patients suggested that the clinicians described the tu-
mours as being a “small” or “slow growing cancer”, and
patients reported being told that surgery would offer a
cure.
“Well actually what he [thyroid surgeon] said to me
was, um, he said, “This is a good result” …Um, he said,
“Because it’s so small and it’s encapsulated and we found
it early and everything”. I said, “So what’s the ramifica-
tions for me?”, and he said, “Basically, once you remove
it that should be end of story”.” (male, age 51–75, imaging
finding)
Patients did not however appear to understand the
natural history and generally indolent nature of PMC.
As such, they did not seem to be aware of the possibility
of overdiagnosis and overtreatment. Some patients
seemed to be conflicted by their cancer diagnosis, as
they understood cancer to be something terrible but
they were told and felt that their cancer was a ‘good
result’.
“I understood that I had, obviously that I had cancer
and to me I just wanted it out, I wanted to be able to
move on with my life and just get it out and let’s be
done with this and let’s get it done as soon as
possible.” (female, age 26–50, imaging finding)
“I think it’s [cancer] built its reputation for a reason I
suppose, that’s the way I look at it, I mean, it’s not to
be taken lightly and, it’s, um, you know, it needs to be,
needs to be addressed as quick as you can and, um,
you know, there’s obviously all, all grades in all types
and what have you but, um, it’s all cancer, isn’t it?”
(male, age 51–75, imaging finding)
Treatment decision making
For the vast majority of patients, they reported that sur-
gery (thyroidectomy or hemi-thyroidectomy) was the
only treatment option recommended or discussed; only
one patient reported being offered the option of active
surveillance. For some patients, total thyroidectomy
was the only treatment suggested, while others were
Nickel et al. BMC Cancer  (2018) 18:242 Page 4 of 10
offered either a total or hemi-thyroidectomy. In some
instances, the clinician offered both options but recom-
mended a hemi-thyroidectomy to try and reduce pos-
sible adverse effects and medication burden for the
patient. Most patients described having discussions
with their clinicians about the risks and side-effects as-
sociated with surgery.
“…because they knew it was there they said they had
to take it out.” (female, age 51–75, imaging finding)
“So he didn’t, I don’t think there was any way to give
me options, you know. The option was ok, we have to
take it out. The only option.” (male, age 51–75,
imaging finding)
Overall, patients placed their trust in their clinician’s
treatment recommendations and did not usually ques-
tion their treatment advice.
“Um, I didn’t ask the question why I need to have the
whole thyroid removed at all, because I just felt they
are the experts.” (female, 51–75, imaging finding)
“I just think I just agreed, um… just agreed to
everything that was, that was happening. Um, I don’t
Table 2 Classification of modes of detection for PMC with patient examples and supporting quotes
Classificationa Description Patient example Supporting quote
Asymptomatic nodule
Physical exam
finding
When a thyroid nodule is found during
a physical exam (thyroid palpation) of a
patient without symptoms concerning
for thyroid disorder
Patient went to a local GP for a check-
up and the GP felt a lump on his throat
“I went to the local doctors just to sign
up, and not that there was anything
wrong with us, but, er, and while we
were talking the doctor said to me,
what’s that lump in your throat?”
Imaging finding When a thyroid nodule is found during
an imaging test requested for reasons
unrelated to a thyroid disorder or
symptom
CT scan for a pinch nerve in patient’s
shoulder
“I was feeling, electrical pulse, pulses
going through my shoulder, through my
arms to my fingers. And, um, that
happened for a few days and then I was
worried and I went to see my GP. [He
said] “… we’re going to do a scan you
might have a pinched nerve or something.””
Diagnostic work
up
When a thyroid nodule is found during
the work up of clinical symptoms or
abnormal laboratory tests that could be
suggestive of thyroid disease or known
thyroid disease
Patient was not feeling well and blood
tests revealed that something may be
wrong in her thyroid
“I just went to see the doctor to just see
you know there might be something
wrong with my chest. So, we did an x-ray
and she said look it’s fine. Everything is
cleared however we’ll just do a blood test
to see if your immunity is maybe a bit
low and that’s where she found that my
thyroid level was a bit playing up. Which
I’d never had any problems before so she
just did another test just to make sure
and that’s when I sort of, that’s when she
sort of found out that there is a bit of a
problem.”
Case finding When a thyroid nodule is found on an
ultrasound performed for thyroid cancer
screening
Patient lived in Belarus during Chernobyl
therefore clinician requested she be
screened
“I’m originally from Belarus, and I’m living
in Australia for the last 4 years and we
have big impact of Chernobyl, what all
my doctors think and the, I didn’t have
any symptoms anything, I just visit, when
I was in Belarus for holidays I just went
for the check-up. And they said that
because of all my friends had similar
problems I thought I just go and check
and they said I have a nodule and then I
was returned to Australia and they started
to keep an eye on it.”
Symptomatic
nodule
When a thyroid nodule is found in a
symptomatic patient
Felt a lump in his neck so went to the
GP to get it checked
“I turned my head I felt strange and I felt
in my throat and, er, there was a lump.
And, um, which I’d never seen before. And
it did come up quite suddenly and it was
visible. Um, so, um, I checked with my GP
who said it was my thyroid, and he
referred me to a specialist.”
aAs classified and described by Singh Ospina et al. 2016 [15]
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think I had… enough time to really, um… digest it.”
(female, age 26–50, symptomatic nodule)
A number of patients did however describe their per-
sonal preference for treatment. Patients who preferred a
total thyroidectomy discussed not feeling comfortable
having something cancerous in their body and not want-
ing to deal with any further risks (including the possibility
of needing further surgery) that may arise. These patients
wanted to take a ‘better safe than sorry’ approach to their
treatment. Patients who reported preferring a hemi-
thyroidectomy discussed the importance of not wanting to
be on thyroid replacement medication for the rest of their
lives. These patients tended to place a high emphasis on
the impact it may have on their lifestyle or had heard stor-
ies about the difficulties and side-effects people encounter
on thyroid replacement medication.
“I wanted everything out of my body. I was happy to
have the thyroidectomy; I just wanted everything that
was cancerous out.” (female, 51–75, imaging finding)
“I’ve heard horror stories… So I’m very wary of taking
medication, because I’ve worked in doctor’s surgeries,
I’ve seen so many people pop pills and not ask why. I
come at that from a very different perspective.”
(female, age 51–75, imaging finding)
Impact of being diagnosed and receiving treatment
Patients experience with physical, emotional or psycho-
logical side-effects varied. Some patients described almost
no side-effects while others had mild to severe side-effects
following their diagnosis and treatment of PMC. Fatigue
was the most common physical side-effect that was dis-
cussed during the interviews. Many patients described hav-
ing fatigue following their surgery and also, many patients
who received a total thyroidectomy described having fa-
tigue upon starting their thyroid replacement medication.
“I’ve had so many times that I’ve felt so tired, I’ve felt
pretty awful a lot of the time since the surgery.”
(female, age 51–75, imaging finding)
Changes in voice and issues with calcium levels following
surgery was also described by a few patients. Some of these
patients described having more difficulty following surgery
than other patients, as they had to stay in the hospital for
longer periods than expected or have additional medication.
“The thing is my voice is not the same. It’s not the
same. Like I’m talking now, sometimes after days,
waiting for days it’s a bit better, but every single day
when I wake up in the morning my voice is, um… oh,
what’s the word? My voice is croaky.” (male, age 51–75,
imaging finding)
“I know they did, um… nic one of the parathyroids
and since I had my thyroid, thyroid out, um… um, I’ve
been just having a lot of trouble with my calcium
levels trying to stabilise my calcium levels. Um, been
in and out of hospital having, um, calcium infusions.”
(female, age 26–50, diagnostic work-up)
In terms of emotional and psychological side-effects, a
number of patients who received either a total thyroidec-
tomy or a hemi-thyroidectomy discussed being continually
worried that the cancer could spread or return. See Fig. 1
Fig. 1 Treatment pathway and important side-effects/consequences of treatment reported by patients
Legend: Solid line (−) = common, Dotted line (–) = less common, *only 1 patient offered active surveillance
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for treatment pathway and important side-effects/conse-
quences of treatment reported by patients.
“I worried all the time, you know, sometimes, even
today, one year after. Even today sometimes I go to
bed and sort of, er, thinking about ok, what’s wrong
with my, er, voice and, and, er, am I going to get
cancer on the other side, or is it going to spread,
you know? I’ve got that worry in my mind all the
time, yeah, there is no doubt.” (male, age 51–75,
imaging finding)
Generally, patients expressed feeling lucky that
their cancer was caught early and that it was treated
quickly.
“I felt very lucky because of, um, it was, you know, a
very early diagnosis really.” (female, age 51–75,
imaging finding)
Terminology and the effect of the cancer term
When patients were asked about different terminology
to describe PMC, which has been proposed by a number
of cancer experts and researchers [4, 16], they generally
seemed unfamiliar with terms other than cancer to de-
scribe their condition. Moreover, patients could not de-
scribe how they might react if their diagnosis called
something other than cancer.
Patients did however describe their experiences when
hearing the word. The effect of being diagnosed with
cancer varied across patients. Many patients described
being in complete shock as they were not expecting a
cancer diagnosis. A few of these patients described feel-
ing panicked and thinking that cancer meant that were
going to die.
“It’s like a, it’s like a freakin’ tsunami…. I think that
“C” word you don’t… you can prepare for it, but you
can never really... understand until you’ve been told,
“You have cancer.”” (male, age 51–75, symptomatic
nodule)
“Well they say it was cancer, I tell you what, I’m
thinking ok, I’m going to die. Whatever they tell me,
ok, I’m going to die soon, I’m going to die.” (male, age
51–75, imaging finding)
On the other hand, a few patients described not feeling
too worried about their diagnosis.
“...if you’re going to have a tumour perhaps that’s not
a bad place to have it.” (female, age 51–75, imaging
finding)
Feelings towards active surveillance
When asked how they would feel, retrospectively, about
active surveillance as a potential management option,
few patients were open to this idea. As mentioned previ-
ously most patients did not like the idea of having a can-
cer inside their body and wanted it removed quickly.
“I just want to get in and get it fixed, I just think with
any type of cancer; I don’t think they should be sitting
in your body. Whether they are slow growing or not I
just don’t think they should be there. And if there is a
way, if it was my body and my choice I want it out as
soon as possible.” (female, age 51–75, imagingl
finding)
However, one patient did suggest he would have liked
to have more information about active surveillance and
when directly asked said he may have chosen it if it was
offered to him at the time.
“I would’ve also liked, um, somebody to be a bit frank
about, um, about the controversy. You know, that,
that... There is a way to follow it up by monitoring.”
(male, age 51–75, imaging finding)
Discussion
In a sample of Australian patients diagnosed with PMC,
the diagnosis and treatment experience varied widely.
The majority of patient’s PMC were asymptomatic and
initially detected via an imaging test requested for a rea-
son unrelated to a thyroid disorder or symptom. This in-
cidental finding of a thyroid nodule led patients down a
diagnostic and treatment cascade, which often resulted
in physical and emotional side-effects.
GPs, who were the first point of contact for patients,
generally did not seem to inform patients about possible
consequences of further testing, as many patients de-
scribed being surprised by their cancer diagnosis and
unaware of the possibility that a cancer could be identi-
fied from the imagining test.
Clinicians (thyroid surgeons or endocrinologists) gen-
erally described PMC to the patients as being a “small”
or “slow-growing” cancer. There was little evidence that
clinicians had discussed the possibility of overdiagnosis
and overtreatment of PMCs with patients. Patients
understood that surgery offered them a cure, but did not
seem to be aware that they might not have needed to be
cured in the first place. According to their reports, sur-
gery was the only management option discussed and of-
fered to the majority of patients. Only one clinician
discussed the option of active surveillance with their pa-
tient. When deciding about the extent of surgery, pa-
tients who preferred a total thyroidectomy valued the
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possibility of reoperation and wanted to get it all re-
moved at once. Patients who preferred to receive a
hemi-thyroidectomy discussed not wanting to be on thy-
roid replacement medication for the rest of their life as
the main reason, although seemed unware that they may
still have a 1 in 3 chance of requiring thyroid replace-
ment medication [17, 18].
When patients were asked about different terminology
to describe PMC, they generally seemed unfamiliar with
terms other than cancer to describe their condition and
could not describe how they might react if their diagno-
sis called something other than cancer. However, as ex-
pected, hearing the cancer term had a major impact on
some patients. These patients described having ongoing
anxiety about their diagnosis and the idea that their can-
cer may return. On the other hand, some patients de-
scribed being unworried about their diagnosis and felt
that thyroid cancer was a ‘good’ cancer if they were go-
ing to get one. Importantly, most patients also felt that
active surveillance is not something that they would be
interested in for their diagnosis. These patients described
not wanting to have a cancer left inside of them and had
a preference for it to be removed quickly.
Implications for research and practice
This study provides insight into PMC patients experi-
ence surrounding diagnosis and treatment communica-
tion and decision making, which may help understand
potential drivers of thyroid cancer overdiagnosis and the
implications for non-surgical management options or
changes in terminology.
Firstly, these findings underscore a need for more in-
formation for health professionals and the public on the
meaning of incidental diagnoses and the possibility of
overdiagnosis, both generically and specifically for thy-
roid cancer.
Avoiding ultrasound guided-biopsy for thyroid nodules
< 1 cm would reduce unnecessary detection of PMC.
Guidelines have advised against biopsy of these small
nodules for a number of years [19] and although there
has been a reported shift in practice [20], as demon-
strated by the patient experiences in this study nodules
< 1 cm are still being biopsied. Providing information to
patients and involving them in the shared decision mak-
ing process, when appropriate, about whether or not to
proceed with the biopsy may be an effective strategy to
reduce unnecessary PMC diagnoses. Providing patients
with decision aids may be one effective strategy [21, 22].
These interviews also showed that patients felt lucky
to be diagnosed early and felt that their life had been
saved by treatment, although several were still burdened
with ongoing physical and emotional side-effects. PMC
patients in this study provide an example of how overdi-
agnosis can create a cycle of positive feedback for more
overdiagnosis, as described by Welch and Black [23]. As
thyroid cancer incidence increases so does population
awareness (e.g. more patients might hear about someone
they know who has been diagnosed with thyroid cancer
and saved). This increased awareness, combined with
the general enthusiasm for early detection, may lead
some people to be diagnosed and receive treatments that
they feel may save their life. For thyroid cancer, the
problem is also compounded by high survival rates that
many may solely attribute to surgical interventions.
Reducing the number of PMC diagnoses is the best
strategy to stop the overdiagnosis cycle; however, if a pa-
tient does receive a diagnosis it is important that clinicians
give a priority to shared decision making when discussing
management options. Evidence suggests that this should
now include discussing the option of active surveillance
with those diagnosed with PMC [24]. Further research is
required to fully understand how a change in terminology
for PMC would impact patients’ treatment decision mak-
ing and psychosocial outcomes as it has been shown for
other lesions with low malignant potential (e.g. ductal car-
cinoma in situ) that removing the term ‘cancer’ from the
diagnosis may help alleviate anxiety, allowing patients to
give greater consideration to more conservative manage-
ment options [25, 26].
Strengths
This is the first qualitative study which explores the
diagnosis and treatment experiences of patients with
small low-risk thyroid cancers. Understanding commu-
nication, decision making and treatment preference sur-
rounding a diagnosis of PMC is important and timely as
evidence surrounding potential overdiagnosis of these le-
sions is emerging and management options are chan-
ging. We specifically only interviewed patients who had
been diagnosed pre-operatively with PMC < 1 cm as
these smaller thyroid tumours are thought to be import-
ant drivers of increasing incidence rates [1], and at this
time, this is the group of patients where active surveil-
lance can be considered as an alternative management
option to immediate surgery [10]. The age and sex dis-
tribution of patients interviewed in this study reflects
what is expected in a thyroid cancer population [1, 5],
however there was a greater proportion of patients with
higher levels of educational attainments which is likely
reflective of higher educated people being more willing
to take part in research.
We used rigorous qualitative methods which included
recruitment of patients from a number of avenues to en-
sure there was a heterogeneous sample of patient experi-
ences, theme saturation, a trained and experienced
qualitative interviewer and a detailed analysis process to
reach the final themes [14].
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Limitations
This study may be limited by the retrospective nature of
the interviews. Interviewing patients during or directly
after their diagnosis and treatment may have revealed
more thorough accounts of the patient’s experience in-
cluding the immediate physical and emotional impact.
However, interviewing patients up to 1 year post-
diagnosis and treatment did allow for patients to reflect
on their experiences. Furthermore, a few of the patients
interviewed were only a few weeks or months after they
had completed their treatment and many patients were
able to discuss their ongoing side-effects or struggles
from their diagnosis and treatment experience.
Also, we only interviewed patients from Australia and
therefore the experiences of PMC patients in other
countries may differ. For example, in Japan where clini-
cians have more experience offering active surveillance
for the management of PMC, patients may be more fa-
miliar and receptive to this option [9, 11]. As all patients
in our study had already received surgery for their diag-
nosis of PMC, attitudes towards active surveillance were
difficult to adequately measure or understand as they
were subjected to biases such as cognitive dissonance.
Conclusions
Evidence continues to emerge that PMCs are being over-
diagnosed, and management guidelines are now recom-
mending more conservative management options for
these lesions. As a result, communicating these issues to
patients with a PMC diagnosis is extremely important and
shared decision making around treatment options is vital.
This will help ensure that patients are fully aware of the
meaning of their diagnosis, their management options, in-
cluding active surveillance, and the associated benefits
and risks. More importantly, interventions to reduce un-
necessary diagnoses of PMC are critically needed. Redu-
cing excessive imaging tests and educating patients about
their choices before having a biopsy will likely reduce un-
necessary physical and psychological harms associated
with overtreatment of this indolent condition.
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